Gynecologic and Obstetric Investigation

Original Article

The Expression of Placental Proteoglycans in Pre-Eclampsia

Chui A.a, b · Murthi P.a, b · Brennecke S.P.a, b · Ignjatovic V.c–e · Monagle P.T.c–e · Said J.M.a, b

Author affiliations

aDepartment of Perinatal Medicine, Pregnancy Research Centre, The Royal Women’s Hospital, bDepartment of Obstetrics and Gynaecology, The University of Melbourne, and cMurdoch Children’s Research Institute and Departments of dClinical Haematology and ePaediatrics, The Royal Children’s Hospital and The University of Melbourne, Parkville, Vic., Australia

Keywords: ProteoglycansPlacentaPre-eclampsiaCoagulation

Related Articles for ""
Gynecol Obstet Invest 2012;73:277–284
https://doi.org/10.1159/000333262

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: April 07, 2011
Accepted: September 12, 2011
Published online: April 19, 2012
Issue release date: June 2012

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 2

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI

Abstract

Background/Aims: Pre-eclampsia (PE) is one of the leading causes of maternal and perinatal morbidity and mortality. PE is defined clinically as the onset of maternal hypertension and proteinuria following 20 weeks of gestation. It is associated with altered maternal uterine decidual spiral artery remodelling, which may lead to reduced blood flow and increased thrombosis within the uteroplacental vasculature. Proteoglycans (PGs) are macromolecules which have (in combination with glycosaminoglycans) important anticoagulant roles in vascular endothelial environments, including the uteroplacental circulation. The hypothesis under consideration in this study was that differential expression of placental PGs may be associated with PE. Methods: PE and control placental samples were collected with ethics approval and patient consent. RNA and protein were extracted and real-time PCR and Western immunoblotting were performed to determine the expression of the PGs in the samples. Results: Of the nine PGs investigated, none showed increased expression, whereas the mRNA and protein expression of five of them was significantly decreased in the placentae of pre-eclamptic women compared to gestation-matched controls. Conclusion: Therefore, the results of this study support the hypothesis that a placental PG deficiency may contribute to the placental thrombotic lesions characteristic of PE.

© 2012 S. Karger AG, Basel



Related Articles:

References

  1. Khan S, Blackburn M, Mao DL, Huber R, Schlessinger D, Fant M: Glypican-3 (GPC3) expression in human placenta: localization to the differentiated syncytiotrophoblast. Histol Histopathol 2001;16:71–78.
    External Resources
  2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R: Pre-eclampsia. Lancet 2010;376:631–644.
    External Resources
  3. Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130–137.
    External Resources
  4. Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK, McMahon LP, Mangos G, Moore MP, Muller P, Paech M, Walters B: Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust NZ J Obstet Gynaecol 2009;49:242–246.
    External Resources
  5. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B: Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension 2011;57:85–93.
    External Resources
  6. Bellamy L, Casas JP, Hingorani AD, Williams DJ: Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007;335:974.
    External Resources
  7. Mongraw-Chaffin ML, Cirillo PM, Cohn BA: Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension 2010;56:166–171.
    External Resources
  8. Roberts JM, Gammill HS: Preeclampsia: recent insights. Hypertension 2005;46:1243–1249.
    External Resources
  9. Khong TY, De Wolf F, Robertson WB, Brosens I: Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986;93:1049–1059.
    External Resources
  10. Lanir N, Aharon A, Brenner B: Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost 2003;29:175–184.
    External Resources
  11. Uszynski M: Generation of thrombin in blood plasma of non-pregnant and pregnant women studied through concentration of thrombin-antithrombin III complexes. Eur J Obstet Gynecol Reprod Biol 1997;75:127–131.
    External Resources
  12. Delorme MA, Xu L, Berry L, Mitchell L, Andrew M: Anticoagulant dermatan sulfate proteoglycan (decorin) in the term human placenta. Thromb Res 1998;90:147–153.
    External Resources
  13. Perrimon N, Bernfield M: Cellular functions of proteoglycans – an overview. Semin Cell Dev Biol 2001;12:65–67.
    External Resources
  14. Swan BC, Murthi P, Rajaraman G, Pathirage NA, Said JM, Ignjatovic V, Monagle PT, Brennecke SP: Decorin expression is decreased in human idiopathic fetal growth restriction. Reprod Fertil Dev 2010;22:949–955.
    External Resources
  15. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(–Delta Delta C(T)) Method. Methods 2001;25:402–408.
    External Resources
  16. Said JM: The role of proteoglycans in contributing to placental thrombosis and fetal growth restriction. J Pregnancy 2011;2011:928381.
  17. Novotny WF, Palmier M, Wun TC, Broze GJ Jr, Miletich JP: Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991;78:394–400.
    External Resources
  18. Elenius K, Maatta A, Salmivirta M, Jalkanen M: Growth factors induce 3T3 cells to express bFGF-binding syndecan. J Biol Chem 1992;267:6435–6441.
    External Resources
  19. Neaud V, Duplantier JG, Mazzocco C, Kisiel W, Rosenbaum J: Thrombin up-regulates tissue factor pathway inhibitor-2 synthesis through a cyclooxygenase-2-dependent, epidermal growth factor receptor-independent mechanism. J Biol Chem 2004;279:5200–5206.
    External Resources
  20. Iacob D, Cai J, Tsonis M, Babwah A, Chakraborty C, Bhattacharjee RN, Lala PK: Decorin-mediated inhibition of proliferation and migration of the human trophoblast via different tyrosine kinase receptors. Endocrinology 2008;149:6187–6197.
    External Resources
  21. Xu G, Guimond MJ, Chakraborty C, Lala PK: Control of proliferation, migration, and invasiveness of human extravillous trophoblast by decorin, a decidual product. Biol Reprod 2002;67:681–689.
    External Resources
  22. Fiedler LR, Schonherr E, Waddington R, Niland S, Seidler DG, Aeschlimann D, Eble JA: Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of alpha2beta1 integrin activity. J Biol Chem 2008;283:17406–17415.
    External Resources
  23. Reigle KL, Di Lullo G, Turner KR, Last JA, Chervoneva I, Birk DE, Funderburgh JL, Elrod E, Germann MW, Surber C, Sanderson RD, San Antonio JD: Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion. J Cell Biochem 2008;104:1684–1698.
    External Resources
  24. Schonherr E, Sunderkotter C, Iozzo RV, Schaefer L: Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 2005;280:15767–15772.
    External Resources
  25. Giri TK, Tollefsen DM: Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood 2006;107:2753–2758.
    External Resources
  26. Rohde LH, Janatpore MJ, McMaster MT, Fisher S, Zhou Y, Lim KH, French M, Hoke D, Julian J, Carson DD: Complementary expression of HIP, a cell-surface heparan sulfate binding protein, and perlecan at the human fetal-maternal interface. Biol Reprod 1998;58:1075–1083.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: April 07, 2011
Accepted: September 12, 2011
Published online: April 19, 2012
Issue release date: June 2012

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 2

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2012, Vol.73, No. 4

June 2012

Article

Recommend This
TOP